Abeona Therapeutics Inc Foglalás / Részvény
Mi az Abeona Therapeutics Inc Foglalás / Részvény?
A Foglalás / Részvény az Abeona Therapeutics Inc - 1.62
Mi a Foglalás / Részvény meghatározása?
Az egy részvényre jutó könyv szerinti érték egy vállalat eszköze, mínusz kötelezettségek, osztva a fennálló részvények számával.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Foglalás / Részvény a Health Care szektor a NASDAQ-on cégekben a Abeona Therapeutics Inc -hoz képest
Mit csinál Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
foglalás / részvény -hoz hasonló cégek Abeona Therapeutics Inc
- Future Generation Global Investment nak Foglalás / Részvény 1.62 van
- Global Value Fund nak Foglalás / Részvény 1.62 van
- Cia Energetica DE Minas Gerais - Cemig nak Foglalás / Részvény 1.62 van
- Dongjiang Environmental nak Foglalás / Részvény 1.62 van
- Homeland Interactive Technology nak Foglalás / Részvény 1.62 van
- Boat Rocker Media nak Foglalás / Részvény 1.62 van
- Abeona Therapeutics Inc nak Foglalás / Részvény 1.62 van
- Uranium Royalty nak Foglalás / Részvény 1.63 van
- Medicure nak Foglalás / Részvény 1.63 van
- Greenpro Capital nak Foglalás / Részvény 1.63 van
- Tse Sui Luen Jewellery (International) nak Foglalás / Részvény 1.63 van
- Trainline Plc nak Foglalás / Részvény 1.63 van
- AWN nak Foglalás / Részvény 1.63 van